Exclusive Webinar: Unpacking the Future of U.S. Drug Pricing Policy
Gain immediate access to actionable insights from CMS and ADVI Health policy leaders.
From the Medicare Drug Price Negotiation Program to Most Favored Nation (MFN) pricing approaches — including the GENEROUS, GLOBE, and GUARD models – and evolving 340B requirements, biopharmaceutical stakeholders are navigating a highly fluid regulatory environment.
Understanding how these policy shifts intersect, and how they directly impact your pricing strategy, product launches, and commercialization plans, is critical for staying competitive.
In the full webinar recording, you’ll learn:
- Where Key Policies Stand: Breakdown of recent developments across Medicare negotiations, MFN models, and 340B reform.
- Commercial and Access Implications: How intersecting state, federal, and global policies influence market access and long-term spending strategies.
- What to Expect Next: Key implementation milestones, unanswered policy questions, and potential risks to pipeline innovation and investment.
Featured Panelists
- Lindsay Bealor Greenleaf — Senior Vice President and Head, Market Access Policy Strategy (MAPS), ADVI Health
- Alicia Silver — Vice President, Emerging Therapies, ADVI Health
- Brenna Raines (Moderator) — Vice President, Market Access Policy Strategy (MAPS), ADVI Health
Complete the form to access the full webinar recording
CEO insights
Related articles
Real analysis from people who’ve been there
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.






